Therapeutic Effect of Tacrosolv in Patients With Allergic Rhinoconjunctivitis
Status:
Active, not recruiting
Trial end date:
2021-10-31
Target enrollment:
Participant gender:
Summary
Allergic conjunctivitis is one of the most common comorbidities of allergic diseases,
especially of allergic rhinitis.
Rhinoconjunctivitis is an allergic condition of the nasal mucosa and the eyes. Conjunctivitis
is triggered by hypersensitivity to certain pollens and other airborne allergens and causes
several symptoms such as reddened eyes, itchy eyes and can cause watery eyes and a scratchy
feeling in the eye. Tacrolimus is a well-known immunosuppressiv active substance which is
hardly soluble in water. Within Tacrosolv, Tacrolimus is completely dissolves in aqueous
solution. The effectiveness of Tacrosolv will be tested for treatment of allergic
conjunctivitis. Allergic subjects will be treated with aqueous formulation of tacrolimus
'Tacrosolv 50 micrograms per milliliter, eye drops' for 8 days. On day 1 and day 8 allergic
patients will be challenged with grass pollen for a period of 4 hours and subjective allergic
symptoms will be assessed.